TRAF3IP2 gene variation (rs13190932) in people with psoriasis and psoriatic arthritis
Genetic Variation in TRAF3IP2 (rs13190932) and Its Association With Psoriasis, Psoriatic Arthritis, and Treatment Outcome With Methotrexate
This trial will test whether the TRAF3IP2 (rs13190932) gene variant changes how adults with psoriasis or psoriatic arthritis respond to methotrexate treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | South Valley University Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Qina) |
| Trial ID | NCT07086924 on ClinicalTrials.gov |
What this trial studies
Adults with confirmed psoriasis or psoriatic arthritis who are starting methotrexate are enrolled and genotyped for the TRAF3IP2 rs13190932 variant. Clinical severity (for example PASI) and safety labs are collected over scheduled follow-up visits to track response and adverse effects while on methotrexate. Patients with other autoimmune diseases, significant liver or kidney impairment, pregnancy/lactation, or on other systemic immunosuppressants are excluded. The approach compares treatment outcomes by genotype to see if the variant predicts methotrexate benefit or toxicity.
Who should consider this trial
Good fit: Adults aged 18–70 with dermatologist- or rheumatologist-confirmed psoriasis vulgaris or psoriatic arthritis who are about to start methotrexate and can attend follow-up visits are ideal candidates.
Not a fit: People who are pregnant or breastfeeding, already on systemic immunosuppressive therapy, have significant liver or kidney disease, other autoimmune disorders, or cannot start methotrexate are unlikely to benefit from joining this trial.
Why it matters
Potential benefit: If successful, the results could help predict who is more likely to benefit from methotrexate and guide more personalized treatment decisions.
How similar studies have performed: Prior genetic studies have linked TRAF3IP2 and other loci to psoriasis risk and some work has explored genetics and methotrexate response, but using rs13190932 specifically to guide methotrexate treatment is relatively novel and not yet proven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 -70years . * the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI \> 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist. * Willingness to participate: Signed informed consent. * Initiating methotrexate (MTX) therapy: For prospective cohort. * Availability for follow-up: Patients must be willing and able to attend scheduled visit. Exclusion Criteria: * Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus). * Pregnancy and lactation. * Patients currently undergoing immunosuppressive or systemic therapies. * Patients with known genetic disorders affect immune system function. * Patients with liver or kidney impairment. * Patients with allergy or contraindication to methotrexate. * Patients with active or uncontrolled infections, including chronic infections like tuberculosis. * Previous genetic analysis Patients who have previously undergone genetic analysis for the TRAF3IP2 gene polymorphism (rs13190932).
Where this trial is running
Qina
- Qena Hospital — Qina, Egypt (Recruiting)
Study contacts
- Study coordinator: Fawzia Mohamed Abd Elzaher, MSC
- Email: drfawzia11111995@gmail.com
- Phone: +201001238064
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.